Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 81, Issue 6, Pages 1124-1133
Publisher
Wiley
Online
2016-02-16
DOI
10.1111/bcp.12907
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 995PDPHASE II STUDY OF LENVATINIB (LEN), A MULTI-TARGETED TYROSINE KINASE INHIBITOR, IN PATIENTS (PTS) WITH ALL HISTOLOGIC SUBTYPES OF ADVANCED THYROID CANCER (DIFFERENTIATED, MEDULLARY AND ANAPLASTIC)
- (2017) S. Takahashi et al. ANNALS OF ONCOLOGY
- A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment
- (2015) Maria E. Cabanillas et al. CANCER
- A randomized, three-treatment, three-period, six-sequence-crossover, single-center, bioequivalence study to evaluate the impact of different 10-mg crystalline forms on the pharmacokinetics of lenvatinib in healthy volunteers
- (2015) Lucy Lee et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers
- (2014) Robert C. Shumaker et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effect of Rifampicin on the Pharmacokinetics of Lenvatinib in Healthy Adults
- (2014) Robert C. Shumaker et al. CLINICAL DRUG INVESTIGATION
- Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers
- (2014) Robert Shumaker et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration
- (2014) Robert Shumaker et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
- (2013) Kiyoshi Okamoto et al. CANCER LETTERS
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
- (2012) D S Boss et al. BRITISH JOURNAL OF CANCER
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models
- (2011) Martin Bergstrand et al. AAPS Journal
- Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
- (2011) K. Yamada et al. CLINICAL CANCER RESEARCH
- Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase
- (2008) J. Matsui et al. CLINICAL CANCER RESEARCH
- Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group
- (2008) Ramesh K. Ramanathan et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search